Use of romidepsin for the treatment of mycosis fungoides and Sezary syndrome – role of romidepsin in the current therapeutic landscape and implications for future practice

Bibliography

• Imam MH, Shenoy PJ, Flowers CR, et al. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma 2013;54:752-9
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-76
   PubMed Web of Science ®Google Scholar
• Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013;149:1295-9
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin’s lymphomas. Version 2. 2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Whittaker SJ, Marsden JR, Spittle M, Jones RR. Joint British association of dermatologists and U.K. cutaneous lymphoma group guidelines for the management of primary cutaneous T-cell lymphomas. Br J Dermatol 2003;149:1095-107
   PubMed Web of Science ®Google Scholar
• Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi149-54
   PubMed Web of Science ®Google Scholar
• Ueda H, Nakajima H, Hori Y, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacteriumviolaceum No. 968. I. taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot 1994;47:301-10
   PubMed Web of Science ®Google Scholar
• Ueda H, Manda T, Matsumoto S, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacteriumviolaceum No. 968. III. antitumor activities on experimental tumors in mice. J Antibiot 1994;47:315-23
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for treatment. J Clin Investig 2014;124:30-9
   PubMed Web of Science ®Google Scholar
• Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28:S3-20
   PubMed Web of Science ®Google Scholar
• Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148:256-67
   PubMed Web of Science ®Google Scholar
• Shiraga T, Tozuka Z, Ishimura R, et al. Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull 2005;28:124-9
   PubMed Web of Science ®Google Scholar
• Bronson J, Dhar M, Ewing W, Lonberg N. To market, to market - 2010: Romidepsin. Annu Rep Med Chem 2011;46:482-3
   Google Scholar
• Woo S, Gardner ER, Chen X, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res 2009;15:1496-503
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robery RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002;8:718-28
   PubMed Web of Science ®Google Scholar
• Fouladi M, Furman WL, Chin T, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a children’s oncology group report. J Clin Oncol 2006;24:3678-85
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, et al. A phase I and pharmacodynamics study of depsipeptide (FK228) in chronic lymphocytic leukaemia and acute myeloid leukaemia. Blood 2005;105:959-67
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 2001;98:2865-8
   PubMed Web of Science ®Google Scholar
• Marshall JL, Rizvi N, Kauh J, et al. A phase II trial of Depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol 2002;2:325-32
   PubMedGoogle Scholar
• Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukaemia or advanced myelodysplastic syndromes. Clin Cancer Res 2008;14:826-32
   PubMed Web of Science ®Google Scholar
• Lunning MA, Ruan J, Nair S, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results. J Clin Oncol 2014;32:Abstract 8582
   Google Scholar
• Dupuis J, Morschhauser F, Ghesquieres H, et al. Final analysis of the RO-CHOP phase Ib/II study: romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL) Abstract 504. Presented at the 56th ASH Annual Meeting; December 6-9, 2014
   Google Scholar
• Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer. Ann Oncol 2010;21:109-13
   PubMed Web of Science ®Google Scholar
• Niesvizky R, Ely S, Mark T, et al. Phase II trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. Cancer 2011;117:336-42
   PubMed Web of Science ®Google Scholar
• Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 2011;117:3658-68
   PubMed Web of Science ®Google Scholar
• Foss F, Coiffier B, Horwitz S, et al. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res 2014;2:16-25
   PubMedGoogle Scholar
• Iwamoto FM, Lamborn KR, Kuhn JG, et al. A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American brain tumor consortium study 03-03. Neuro Oncol 2011;13:509-16
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27:5410-17
   PubMed Web of Science ®Google Scholar
• Piekarz RL, Frye AR, Wright JJ, et al. Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006;12:3762-73
   PubMed Web of Science ®Google Scholar
• Noonan AM, Eisch RA, Liewehr DJ, et al. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for KATP channel. Clin Cancer Res 2013;19:3095-104
   PubMed Web of Science ®Google Scholar
• Godfrey CJ, Cabell CH, Balser B, et al. Exposure-QTc response analysis of class I selective histone deacetylase inhibitor romidepsin Abstract 2680. Presented at 53rd ASH Annual Meeting, 10 – 13 December 2011, San Diego
   Google Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood 2009;114:4337-45
   PubMed Web of Science ®Google Scholar
• Hughes CFM, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood 2015;125:71-81
   PubMed Web of Science ®Google Scholar
• Bates SE, Eisch R, Ling A, et al. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data. Br J Haematol 2015;170:96-109
   PubMed Web of Science ®Google Scholar
• Foss F, Advani R, Duvic M, et al. A phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol 2015;168:811-19
   PubMed Web of Science ®Google Scholar
• Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma Abstract 1742. Presented at ASH Annual Meeting, 6 – 9 December 2014, San Francisco
   Google Scholar
• O’Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (RR/PTCL): results from the BELIEF trial. J Clin Oncol 2013;31(Suppl):Abstract 8507
   Google Scholar
• Luchenko VL, Litman T, Chakraborty AR, et al. Histone deacetylase inhibitor-mediated cell death is distinct from its global effect on chromatin. Mol Oncol 2014;8:1379-92
   PubMed Web of Science ®Google Scholar
• Jain S, Jirau-Serrano X, Zullo KM, et al. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res 2015;21:2096-106
   PubMed Web of Science ®Google Scholar
• Fanale MA, Hagemeister FB, Fayad L, et al. A phase I trial of alisertib plus romidepsin for relapsed/refractory aggressive B- and T-cell lymphomas Abstract 1744. Presented at ASH Annual Meeting, 6 – 9 December 2014, San Francisco
   Google Scholar
• Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepstin in patients with peripheral T-cell lymphoma. Blood 2011;117:5827-34
   PubMed Web of Science ®Google Scholar
• Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, open-label phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012;30:631-6
   PubMed Web of Science ®Google Scholar
• Whittaker SJ, Demierre M-F, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485-91
   PubMed Web of Science ®Google Scholar